January 2024 in “International Journal of Biology Sciences” Targeted interventions based on gender, education, and age can improve COVID-19 healthcare responses.
September 2023 in “JP Journal of Biostatistics” The random forest model effectively helps diagnose COVID-19 using key factors like age and symptoms.
November 2022 in “Journal of the Endocrine Society” A woman with ectopic Cushing's syndrome and COVID-19 passed away despite treatment.
September 2021 in “RECISATEC - REVISTA CIENTÍFICA SAÚDE E TECNOLOGIA - ISSN 2763-8405” Platelet-rich plasma helps treat post-COVID-19 hair loss and boosts self-esteem.
867 citations
,
November 2020 in “Nature Communications” Collider bias can distort our understanding of COVID-19 risk and severity.
36 citations
,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
32 citations
,
June 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” Fatigue is the most common symptom in both ongoing symptomatic COVID-19 and post-COVID-19 syndrome.
5 citations
,
July 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.
Lower LDL-c levels predict higher COVID-19 mortality.
December 2022 in “Urology Herald” Hormonal status from androgen deprivation therapy may affect COVID-19 severity in men.
September 2020 in “arXiv (Cornell University)” Some existing drugs and natural products might work against COVID-19 by targeting the virus's main protease.
February 2023 in “Journal of clinical medicine research” Zinc acetate hydrate may help reduce fatigue and hair loss in post-COVID-19 patients.
Sex hormones likely did not affect COVID-19 outcomes in South Korea.
4 citations
,
May 2021 in “Journal of The American Academy of Dermatology” There's no significant genetic link between male pattern baldness and COVID-19.
27 citations
,
January 2020 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” Healthcare workers in Turkey experienced more skin problems due to frequent handwashing and wearing masks and gloves during the COVID-19 outbreak.
Icosapent ethyl may help treat long-lasting symptoms after COVID-19.
3 citations
,
January 2025 in “Scientific Reports” Cepharanthine is safe but not effective in significantly reducing COVID-19 recovery time.
2 citations
,
January 2021 in “Signa Vitae” Certain symptoms and patient profiles, like thoracic pain and general malaise, increase the risk of COVID-19 patients being readmitted to the emergency department.
1 citations
,
January 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” Cepharanthine is safe but not clearly effective in speeding up COVID-19 recovery.
June 2022 in “Organic communications” Natural compounds, especially Withaferin-A, may help treat post-COVID-19 complications, but some may have side effects.
January 2023 in “Brazilian Journals Editora eBooks” Nursing staff's mental health was affected during the COVID-19 pandemic.
70 citations
,
July 2020 in “Pharmacological Reports” Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.
16 citations
,
December 2020 in “International Journal of Clinical Practice” The pandemic changed how often certain skin conditions were diagnosed.
21 citations
,
January 2021 in “Journal of infection and chemotherapy” Men, diabetes, and high inflammation levels lead to higher COVID-19 antibodies.
1 citations
,
May 2022 in “Голова и шея.” Physical activity increased, but sedentary behavior also rose, especially in men.
4 citations
,
April 2022 in “Dermatologic Therapy” Injecting scalp tissue micrografts is a safe and effective treatment for hair loss after COVID-19.
4 citations
,
February 2022 in “Journal of Cosmetic Dermatology” Monocytes might be linked to hair loss after COVID-19.
13 citations
,
September 2023 in “Medical Gas Research” Nitric oxide may help treat COVID-19 pneumonia by fighting the virus and easing symptoms.
34 citations
,
February 2023 in “Frontiers in Public Health” Hospitalized COVID-19 survivors have a higher risk of long-term symptoms and need special care.